BSE filing, NSE: AMANTA. Summary written from the filing by ALFA Finder's alert engine.
Amanta Healthcare Ltd: key numbers
- Share price
- ₹163.31
- Market cap
- ₹634.1 Cr
- Revenue (annual)
- ₹287.7 Cr
- Net profit (annual)
- ₹14.88 Cr
- P/E (TTM)
- 43.2×Sector 48.7×
- Promoter holding
- 63.80%+0.00% QoQ
- FII holding
- 0.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Amanta Healthcare Ltd
All →Amanta Healthcare Management Change
Amanta Healthcare's COO Shri Anil Rathi resigned effective October 29, 2026. The departure is disclosed under Regulation 30 of the SEBI Listing Regulations.
Amanta Healthcare Board Meeting Date
Amanta Healthcare intimated a Board Meeting scheduled for 3 Nov 2026 to approve Q1 & H1 FY27 unaudited results. Trading window reopens on 6 Nov 2026.
Amanta Healthcare Other Announcement
Amanta Healthcare Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Amanta Healthcare Promoter Selling (Off-Market)
Pravinchandra Dhanjibhai Mehta, a promoter group member of Amanta Healthcare, disposed of 17,32,763 equity shares via an off-market gift. His stake decreased from 4.72% to 0.26%.
Amanta Healthcare Promoter Selling (Off-Market): ₹2.86 Cr
Promoter Pravinchandra Mehta sold 1,50,400 shares of Amanta Healthcare to fellow promoter Kirit Desai in an off-market inter-se transfer valued at ₹2.86 Crore.
- Value
- ₹2.86 Cr
Amanta Healthcare Promoter Buying (Off-Market): ₹2.86 Cr
Amanta Healthcare reported an inter-se off-market transfer of 1,50,400 equity shares between promoter group members. Kirit Ambalal Desai acquired the stake valued at ₹2.86 Crore from Pravinchandra Dhanjibhai Mehta.
- Value
- ₹2.86 Cr
- Promoter stake change
- +0.39%
Other board meeting date announcements
All →Premier Synthetics Board Meeting Date
Premier Synthetics announced its Board of Directors meeting scheduled for 14 November 2026 to consider unaudited Q2 and H1 results. No financial figures or decisions are reported in this advance notice.
HCP Plastene Bulkpack Board Meeting Date
HCP Plastene Bulkpack scheduled a board meeting for 06 November 2026. It will consider unaudited results for the quarter and half year ending 30 September 2026.
Ultracab (India) Board Meeting Date
Ultracab (India) Ltd intimated that its Board meeting is scheduled for 04-Nov-2026 to consider unaudited standalone financial results. No results or financial figures are disclosed in this advance notice.
Texmaco Infrastructure & Holdings Board Meeting Date
Texmaco has scheduled a Board meeting on November 5, 2026, to approve Q2 and H2 FY27 financial results. Trading window stays closed for insiders pending results declaration.
Astonea Labs Board Meeting Date
Astonea Labs intimated that its Board is scheduled on 14 Nov 2026 to consider unaudited half-year results. The trading window remains closed until 48 hours post-announcement.
AstraZeneca Pharma India Board Meeting Date
AstraZeneca Pharma India scheduled its board meeting for 5 Nov 2026 to approve Q2/H1 FY27 results. The trading window remains closed until 7 Nov 2026.